Friday, April 10, 2026
← Back to archivePolicy
Policy•Fierce Biotech•Apr 9, 2026
Philips recalls Trilogy Evo ventilator software, warns of ‘under-delivery’ of therapy
background ▾
- •Class I recall of Trilogy Evo ventilator software affecting 113,700+ devices globally—highest FDA severity classification
- •Software defect causes discrepancy between prescribed and delivered tidal volume, risking under-treatment of ventilator-dependent patients
- •Part of a pattern: Philips has faced multiple major recalls (5.5M devices in 2021, DreamStation 2 overheating in 2023) suggesting systemic quality or design issues requiring sustained monitoring
PhilipsTrilogy EvoTrilogy Evo O2Trilogy Evo Universal
→ Read original articlePolicy•STAT News•Apr 9, 2026
New rules for CDC vaccine panel aim to address lawsuit, empower Kennedy’s allies
background ▾
- •ACIP charter revised to weaken expertise requirements and add vaccine-skeptic liaison organizations, directly responding to federal court challenge and empowering RFK Jr.'s anti-vaccine network
- •New qualifications add toxicology, pediatric neurodevelopment, and "recovery from serious vaccine injuries" expertise, signaling policy shift toward emphasizing vaccine harms over benefits
- •Watch for immediate legal challenges to the revised charter and downstream impact on routine childhood vaccine recommendations, which have traditionally informed state school attendance requirements
Policy•Fierce Biotech•Apr 10, 2026
Chutes & Ladders—Former TreeFrog CEO leaps to Orano Med
background ▾
- •This is a routine industry personnel roundup with no single transformational appointment or departure
Orano MedTreeFrog TherapeuticsIdorsiaAlphaMedix
→ Read original articlePolicy•Fierce Pharma•Apr 10, 2026
RFK Jr. launching health podcast to expose ‘hypocrisy’ and ‘corruption’
background ▾
- •RFK Jr.'s podcast announcement reflects ideological positioning as HHS Secretary with potential implications for FDA/CDC policy direction and pharma regulation
- •Unclear whether this represents informal messaging or signals formal policy changes to pharmaceutical approval, pricing, or vaccine/therapeutic approaches
Policy•Fierce Pharma•Apr 10, 2026
Steven Ubl set to depart after more than a decade as CEO of PhRMA
background ▾
- •Steven Ubl's departure after 10+ years ends a lengthy tenure at the helm of the industry's most influential trade group during a period of intense scrutiny over drug pricing and patent policy
- •The leadership transition occurs amid ongoing political pressure on pharmaceutical pricing and raises questions about the direction of industry advocacy strategy under new leadership
PhRMA
→ Read original articleMarket Access
Market Access•Fierce Biotech•Apr 9, 2026
Boehringer hands over funding, marketing rights for Click’s digital therapeutic
background ▾
- •Boehringer cedes full commercial control of CT-155 to Click Therapeutics while committing $50M Series D investment and undisclosed commercial funding, signaling confidence in the asset despite taking a back-seat commercial role
- •CT-155 demonstrated statistically significant efficacy in Phase 3 for schizophrenia negative symptoms (primary endpoint met), positioning it as a potential first-mover in the prescription digital therapeutics space for psychiatric disease
- •Watch for FDA submission timeline and approval decision for CT-155; monitor Click's ability to execute commercialization independently and establish payer reimbursement pathways for digital therapeutics in psychiatry
Boehringer IngelheimClick TherapeuticsDassault SystèmesCT-155
→ Read original articleMarket Access•Fierce Biotech•Apr 9, 2026
J&J launches latest version of its pulsed ablation device after nabbing CE Mark
background ▾
- •Varipulse Pro represents meaningful product iteration addressing procedural speed and safety, launching in Europe amid upcoming trial data presentation at EHRA
- •U.S. market access remains constrained by post-approval safety signal (four strokes); relaunch with restricted guidance suggests manageable but not resolved safety profile
- •Upcoming 12-month Varipure results will be critical to validate the safety and efficacy improvements claimed for the Pro model and determine trajectory of U.S. commercial recovery
Johnson & JohnsonVaripulse ProVaripulse
→ Read original articleMarket Access•Pharmaceutical Technology•Apr 10, 2026
Gan & Lee and JW Pharmaceutical agree on bofanglutide commercialisation
background ▾
- •Gan & Lee's bi-weekly GLP-1RA bofanglutide has secured its third major geographic licensing deal, signaling confidence in the asset's commercial potential despite crowded GLP-1 market
- •South Korea partnership values bofanglutide at $81.1M+ in total deal value, suggesting meaningful confidence in the dosing advantage and metabolic disease market opportunity in the region
- •Monitor Phase III readout timing and regulatory pathway in South Korea; competitive landscape with established weekly GLP-1s (semaglutide, tirzepatide) and emerging bi-weekly agents will determine market positioning
Gan & Lee PharmaceuticalsJW Pharmaceuticalbofanglutide
→ Read original articleMarket Access•Fierce Biotech•Apr 10, 2026
China’s Oricell raises $110M for carcinoma CAR-T plans ahead of IPO push
background ▾
- •Oricell has now raised over $110 million in a pre-IPO round, bringing total funding to approximately $350+ million since 2015, signaling strong investor confidence in its HCC CAR-T program ahead of public markets entry.
- •Ori-C101 phase 1 data in HCC (n=10) showed objective responses at highest dose, but this is early-stage evidence in a small cohort; pivotal trial success and regulatory approval timelines remain unproven.
- •Watch for: Oricell's IPO filing and valuation; phase 2 efficacy and safety data for Ori-C101; competitive landscape developments from other HCC CAR-T programs; in vivo CAR-T program progress.
Oricell TherapeuticsVivo CapitalBeijing Medical and Health Care Industry Investment FundOri-C101
→ Read original articleMarket Access•Fierce Pharma•Apr 10, 2026
Novartis pumps up community health footprint to tackle heart disease and cancer
background ▾
- •Novartis is significantly expanding community health programs with a target to triple operational footprint by 2030
Novartis
→ Read original articleClinical Trials
Clinical Trials•Fierce Biotech•Apr 9, 2026
In a first, a CAR-T cell therapy drives 3 autoimmune diseases into remission in a single patient
background ▾
- •Zorpo-cel achieved simultaneous remission of three unrelated B-cell-driven autoimmune diseases in a single patient with durable response at 11 months, establishing proof-of-concept for CAR-T's mechanism of immune system 'reset' in autoimmune indications beyond oncology.
- •CAR-T therapy demonstrates superior B-cell depletion depth compared to rival approaches like T-cell engagers, with the treated patient achieving remission where prior treatment with Amgen's Blincyto had failed.
- •Monitor Kyverna's miv-cel FDA submission timeline and efficacy readout for stiff-person syndrome as the likely first autoimmune CAR-T approval; track Miltenyi's phase 1/2 lupus trials and competitive positioning as multiple players (Gilead, UCB, Candid, Oblenio) pursue immune reset strategies.
Miltenyi BiomedicineKyverna TherapeuticsGilead Scienceszorpocabtagene-autoleucelmiv-celBlincyto
→ Read original articleClinical Trials•Fierce Biotech•Apr 9, 2026
'It’s going to be huge': The 'diabolical' molecule poised to become biotech's next gold rush
background ▾
- •Pelacarsen Phase 3 Horizon trial readout imminent (within months) with potential to validate entire Lp(a)-lowering drug class targeting ~65M Americans with elevated risk
- •Market potential could rival or exceed statins if primary prevention efficacy is demonstrated, though major uncertainties remain about patient populations and clinical endpoints
- •Multiple companies pursuing different modalities (ASOs, siRNAs, combination therapies with PCSK9 inhibitors), suggesting broad confidence in the mechanism despite fundamental knowledge gaps about Lp(a) physiology
NovartisIonis PharmaceuticalsAmgenpelacarsenPCSK9 inhibitors
→ Read original articleClinical Trials•Pharmaceutical Technology•Apr 10, 2026
Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers
background ▾
- •Biomarker-driven precision immunotherapies are now foundational to modern oncology, with early biomarker integration from preclinical stages critical to reducing development costs and accelerating regulatory timelines.
- •FDA's requirement for contemporaneous companion diagnostic approval presents a significant operational challenge that can delay market entry if CDx development is not strategically aligned with drug development.
- •The immuno-oncology landscape is expanding beyond checkpoint inhibitors to include CAR-T, TILs, bispecific antibodies, cytokines, and oncolytic viruses, with novel combination strategies expected to drive future growth.
Caidya
→ Read original articleClinical Trials•Fierce Pharma•Apr 10, 2026
Vanda initiates study of motion sickness drug Nereus in GLP-1 users
background ▾
- •Vanda is pursuing a significant market expansion for Nereus by targeting the large and growing population of GLP-1 agonist users who experience nausea and vomiting—a common and dose-limiting side effect
- •Phase 3 initiation signals Vanda's confidence in Nereus's potential in this indication and could substantially broaden the drug's addressable market beyond traditional motion sickness indications
- •Watch for Phase 3 enrollment pace and interim efficacy signals, as well as whether successful results could lead to label expansion or combination therapy positioning with major GLP-1 manufacturers
Vanda PharmaceuticalsNereusmeclizine
→ Read original articleClinical Trials•Fierce Pharma•Apr 10, 2026
Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs
background ▾
- •Avalyn is advancing inhaled reformulations of approved drugs into phase 3, a lower-risk development strategy that leverages existing safety/efficacy data
- •IPO financing signals investor confidence in the reformulation approach but also indicates reliance on public markets for capital
- •Success depends on demonstrating clinical differentiation (improved efficacy, tolerability, or convenience) over established inhaled competitors
Avalyn Pharma
→ Read original article